Schantl, Antonia E.
Verhulst, Anja
Neven, Ellen
Behets, Geert J. http://orcid.org/0000-0001-8697-433X
D’Haese, Patrick C.
Maillard, Marc http://orcid.org/0000-0001-6428-0046
Mordasini, David
Phan, Olivier
Burnier, Michel
Spaggiari, Dany
Decosterd, Laurent A. http://orcid.org/0000-0002-9840-1325
MacAskill, Mark G. http://orcid.org/0000-0001-5355-3109
Alcaide-Corral, Carlos J.
Tavares, Adriana A. S.
Newby, David E.
Beindl, Victoria C.
Maj, Roberto
Labarre, Anne
Hegde, Chrismita
Castagner, Bastien
Ivarsson, Mattias E.
Leroux, Jean-Christophe http://orcid.org/0000-0001-5601-1292
Funding for this research was provided by:
Scholarship Fund of the Swiss Chemical Industry
Article History
Received: 12 April 2019
Accepted: 18 December 2019
First Online: 5 February 2020
Competing interests
: M.I., J.C.L., and B.C. are co-inventors of patents licensed to Inositec Inc. and shareholders thereof. Inositec’s lead compound INS-3001 ((OEG<sub>2</sub>)<sub>2</sub>-IP4) is in development for the prevention and treatment of diseases driven by cardiovascular calcification. The remaining authors declare no competing interests.